Pharma Stocks Heat Up: Athira Pharma ATHA Explodes 70% Following Strategic Asset Acquisition

ZenZKPlayer · 2025-12-26T05:46:07+00:00

Athira Pharma's stock surged 69.53% to $7.01 after announcing a pivotal acquisition of lasofoxifene for metastatic breast cancer treatment. The increased trading volume indicates strong investor interest in the company's expanding oncology pipeline.

ZenZKPlayer

2025-12-26 05:46:07

Abstract generation in progress

Trading action in pharma stocks intensified Thursday as Athira Pharma Inc. (ATHA) shares rocketed higher, closing at $7.01 after gaining $2.88—a dramatic 69.53% jump from Wednesday’s $4.14 close on Nasdaq. The biotech company’s stock opened at $7.22 and traded within a range of $6.77 to $8.35, with exceptional liquidity as volume surged to 53.19 million shares, crushing the typical daily average of 30,063.

The catalyst driving this pharma stock surge was Athira’s announcement of a transformative acquisition agreement to secure global development and commercialization rights to lasofoxifene, a late-stage asset already positioned at Phase 3 for metastatic breast cancer treatment. The clinical-stage biopharmaceutical company’s pipeline expansion into an advanced-stage oncology program resonated strongly with investors seeking exposure to later-stage de-risked assets.

Market technicals reflect the enthusiasm, with ATHA now trading near the upper end of its 52-week range, bouncing from a low of $2.20 to its recent high of $8.35. The substantial volume accompanying Thursday’s move underscores genuine institutional and retail interest in the company’s strategic direction within the competitive pharma stocks landscape.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.